Situation.
Manufacturer with approximately EUR 500m revenue producing across five sites, with a 3:1 spread in fully loaded unit cost.
Manufacturing footprint.
European medical device manufacturer
Challenge.
Consolidation carried regulatory, quality and transfer risks that varied by product line. Revalidation alone required 9–18 months per line.
What we did.
Assessed footprint options on landed cost, risk and capability, and developed a phased transfer plan.
The outcome.
Consolidation from five sites to three, with approximately EUR 18m annual cost reduction at full run-rate. Transfers were sequenced to keep regulatory risk within tolerance.
Anonymised engagement. Figures are approximate. Targets, assessed potential, approved programmes and realised results are described separately in the outcome. Converted amounts use ECB reference rates dated 18 September 2026, rounded to two significant figures.
More Operating Model cases →Facing a similar challenge?
Contact Bearaco’s partners
Let's talk